Eli Lilly and Company $LLY Stock Holdings Increased by Turtle Creek Wealth Advisors LLC

Turtle Creek Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 28,640 shares of the company’s stock after purchasing an additional 822 shares during the period. Eli Lilly and Company makes up about 1.7% of Turtle Creek Wealth Advisors LLC’s portfolio, making the stock its 10th biggest position. Turtle Creek Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $33,138,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $13,522,666,000. Jupiter Topco LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at $4,667,180,000. Fifth Third Bancorp grew its holdings in shares of Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Eli Lilly and Company by 353.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock valued at $1,425,859,000 after acquiring an additional 1,208,510 shares during the period. Finally, Corient Private Wealth LP acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $764,116,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 3.7%

LLY stock opened at $1,253.94 on Friday. The firm’s fifty day simple moving average is $1,178.66 and its 200-day simple moving average is $1,106.93. The company has a market capitalization of $1.18 trillion, a P/E ratio of 42.08, a price-to-earnings-growth ratio of 1.58 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the business earned $6.31 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 34.28 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh data strengthen Lilly’s immunology franchise. In the LUCENT-2 trial, 27.7% of ulcerative-colitis patients achieved comprehensive disease control after one year, including symptomatic, endoscopic and histologic remission, normalized biomarkers and no corticosteroid use. In the VIVID-1 Crohn’s disease trial, 20.4% achieved corticosteroid-free deep remission. The results also included patients who had previously failed biologic therapies, potentially supporting Omvoh’s commercial positioning. Omvoh clinical data
• Positive Sentiment: Pipeline expansion adds longer-term growth potential. Lilly announced oncology collaborations with Adlai Nortye and Prelude Therapeutics, including evaluation of Adlai’s investigational AN4035 with cetuximab. The partnerships broaden Lilly’s cancer research pipeline and exposure to the growing oncology market. Adlai Nortye collaboration
• Neutral Sentiment: Additional pipeline updates provide background support. Lilly is advancing studies of donanemab in India and lebrikizumab in eczema, while investors remain focused on the potential of retatrutide and other next-generation weight-loss treatments.
• Neutral Sentiment: Upcoming earnings could add volatility. Lilly will report third-quarter 2026 results on October 29. Expectations center on continued strong revenue and earnings growth, particularly from its diabetes and obesity medicines. Lilly earnings announcement
• Negative Sentiment: Valuation remains a risk. After a substantial multiyear rally and trading near its 52-week high, Lilly’s premium valuation leaves the stock dependent on continued exceptional growth and successful pipeline execution. Speculation about a stock split is not a fundamental catalyst.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $1,500.00 target price on shares of Eli Lilly and Company in a research note on Monday. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Bank of America increased their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Finally, Guggenheim raised their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.